Building Genetic Medicine
Breast Cancer, Technology and the Comparative Politics of Health Care
Seiten
2007
MIT Press (Verlag)
978-0-262-16242-5 (ISBN)
MIT Press (Verlag)
978-0-262-16242-5 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
A comparative study of genetic testing for breast and ovarian cancer in the United States and Britain that shows the importance of national context in the development and use of science and technology even in an era of globalization.
In Building Genetic Medicine, Shobita Parthasarathy shows how, even in an era of globalization, national context is playing an important role in the development and use of genetic technologies. Focusing on the development and deployment of genetic testing for breast and ovarian cancer (known as BRCA testing) in the United States and Britain, Parthasarathy develops a comparative analysis framework in order to investigate how national "toolkits" shape both regulations and the architectures of technologies and uses this framework to assess the implications of new genetic technologies. Parthasarathy argues that differences in the American and British approaches to health care and commercialization of research led to the establishment of different BRCA services in the two countries. In Britain, the technology was available through the National Health Service as an integrated program of counseling and laboratory analysis, and was viewed as a potentially cost-effective form of preventive care. In the United States, although BRCA testing was initially offered by a number of providers, one company eventually became the sole provider of a test available to consumers on demand.
Parthasarathy draws lessons for the future of genetic medicine from these cross-national differences, and discusses the ways in which comparative case studies can inform policy-making efforts in science and technology.
In Building Genetic Medicine, Shobita Parthasarathy shows how, even in an era of globalization, national context is playing an important role in the development and use of genetic technologies. Focusing on the development and deployment of genetic testing for breast and ovarian cancer (known as BRCA testing) in the United States and Britain, Parthasarathy develops a comparative analysis framework in order to investigate how national "toolkits" shape both regulations and the architectures of technologies and uses this framework to assess the implications of new genetic technologies. Parthasarathy argues that differences in the American and British approaches to health care and commercialization of research led to the establishment of different BRCA services in the two countries. In Britain, the technology was available through the National Health Service as an integrated program of counseling and laboratory analysis, and was viewed as a potentially cost-effective form of preventive care. In the United States, although BRCA testing was initially offered by a number of providers, one company eventually became the sole provider of a test available to consumers on demand.
Parthasarathy draws lessons for the future of genetic medicine from these cross-national differences, and discusses the ways in which comparative case studies can inform policy-making efforts in science and technology.
Shobita Parthasarathy is Associate Professor at the Gerald R. Ford School of Public Policy at the University of Michigan.
| Erscheint lt. Verlag | 8.5.2007 |
|---|---|
| Reihe/Serie | Inside Technology |
| Zusatzinfo | 9 figures, 7 tables |
| Verlagsort | Cambridge, Mass. |
| Sprache | englisch |
| Maße | 152 x 229 mm |
| Gewicht | 567 g |
| Themenwelt | Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik |
| Studium ► Querschnittsbereiche ► Prävention / Gesundheitsförderung | |
| ISBN-10 | 0-262-16242-3 / 0262162423 |
| ISBN-13 | 978-0-262-16242-5 / 9780262162425 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Eine sehr persönliche Geschichte | Der New York Times-Bestseller
Buch | Softcover (2023)
Ullstein Taschenbuch Verlag
CHF 30,75
Die revolutionäre Medizin von morgen (Lifespan)
Buch | Softcover (2020)
DuMont Buchverlag
CHF 22,40
